Blyth Group manages an active portfolio in the fields of technology, real estate and health care. Early stage support is provided to people and ideas with global impact. Current investments include:
VITALL works to empower your health journey.
VITALL safely acquires, secures, and curates your health information, empowering your health journey and enhancing your medical readiness. Right now, your health information is all over the place. Your family doctor, hospitals you’ve visited, that clinic from your vacation. No one has your total health picture. VITALL changes that.
CitiIQ is a measurement system for the health and well-being of a city.
Over the next 30 years, global trends are expected to result in urban growth equating to 250 additional cities with a population of 10 million. CitiIQ is working to become the global standard of measurement for the health and well-being of cities. It has created a proprietary diagnostic tool that objectively measures the social, environmental and economic infrastructure of a city, based on 35 Considerations (areas of concern), within 5 Dimensions (priority levels), through over 120 data driven Indicators (measurements).
Triumvira Immunologics is developing a novel platform for engineering T cell therapies to attack multiple cancers.
Tirumvira is perfecting a process that is safer and more effective than current cancer treatments. It involves removing white blood cells from patients and using genetic engineering to direct the T cells to recognize a protein found on the surface of certain cancer cells. The reprogrammed T cells are re-introduced to the patient to locate and eradicate cancer cells. The company is also developing a series of products to respond to solid tumours.
Appili Therapeutics is advancing the global fight against infectious disease and the
mounting threat of drug-resistant pathogens.
Founded by a team of experts in drug development, infectious disease and commercialization experts, Appili’s approach focuses on matching clearly defined medical/patient needs with drug development programs and opportunities. Its first New Drug Application (NDA) is being submitted to the U.S. Food and Drug Administration (FDA) in 2018.
Satellos has discovered a novel method to modulate the orientation by which stem cells divide and replenish.
It has shown its potential relevance to the treatment of Duchenne Muscular Dystrophy (DMD), a severe genetic disease among children, which currently leads to death in early adulthood. Satellos is advancing its drug discovery and development activities in DMD and other musculoskeletal diseases, and expanding its polarity regulating platform into neuronal cell regeneration.
Greenbrook TMS NeuroHealth Centers treats patients who are struggling with depression.
Transcranial Magnetic Stimulation Therapy (TMS) is a safe and effective treatment for individuals diagnosed with Major Depressive Disorder (MDD) who have not experienced satisfactory improvement from antidepressant medication. TMS Therapy can be used in conjunction with medication or as a stand-alone treatment. It works by delivering magnetic pulses to areas of the brain involved in mood regulation – areas known to be underactive in those diagnosed with MDD. By stimulating brain cell activity, the magnetic pulses encourage mood regulatory function in the brain.